title: LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
abstract: PIK3CA is the most frequent somatic mutated oncogene in estrogen receptor (ER) positive breast cancer. We previously observed an association between PIK3CA genotype and aromatase inhibitors (AI) treatment outcome. This study now evaluates whether expression of mRNAs and miRs are linked to PIK3CA genotype and are independently related to AI therapy response in order to define potential expressed biomarkers for treatment outcome.
  
  
  
  The miR and mRNA expression levels were evaluated for their relationship with the PIK3CA genotype in two breast tumor datasets, i.e. 286 luminal cancers from the TCGA consortium and our set of 84 ER positive primary tumors of metastatic breast cancer patients who received first line AI. BRB Array tools class comparison was performed to define miRs and mRNAs whose expression associate with PIK3CA exon 9 and 20 status. Spearman correlations established miR-mRNA pairs and mRNAs with related expression. Next, a third dataset of 25 breast cancer patients receiving neo-adjuvant letrozole was evaluated, to compare expression levels of identified miRs and mRNAs in biopsies before and after treatment. Finally, to identify potential biomarkers miR and mRNA levels were related with overall survival (OS) and progression free survival (PFS) after first-line AI therapy.
  
  
  
  Expression of 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) and 9 mRNAs (CCNO, FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, SORBS2, VTCN1) was related to the PIK3CA status in both datasets. All except miR-301a-3p had an increased expression in tumors with PIK3CA mutations. Validation in a publicly available dataset showed that LRG1, PGR, and SERPINA3 levels were decreased after neo-adjuvant AI-treatment. Six miR-mRNA pairs correlated significantly and stepdown analysis of all 12 factors revealed 3 mRNAs (PLCL1, LRG1, FAM81B) related to PFS. Further analyses showed LRG1 and PLCL1 expression to be unrelated with luminal subtype and to associate with OS and with PFS, the latter independent from traditional predictive factors.
  
  
  
  We showed in two datasets of ER positive and luminal breast tumors that the expression of 3 miRs and 9 mRNAs associate with the PIK3CA status. Expression of LRG1 is independent of luminal (A or B) subtype, decreased after neo-adjuvant AI-treatment, and is proposed as potential biomarker for AI therapy outcome.
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: d.ramirezardila@erasmusmc.nl.
authors: Diana E
authors: DE
authors: Ramirez-Ardila
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: k.ritstier@erasmusmc.nl.
authors: Kirsten
authors: K
authors: Ruigrok-Ritstier
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: j.helmijr@erasmusmc.nl.
authors: Jean C
authors: JC
authors: Helmijr
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: m.look@erasmusmc.nl.
authors: Maxime P
authors: MP
authors: Look
authors: Department Oncology, Catholic University Leuven, Leuven, Belgium; Translational Cancer Research Unit, Laboratory of Pathology, Antwerp University, Antwerp, Belgium; Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium. Electronic address: s.vanlaere@gza.be.
authors: Steven
authors: S
authors: van Laere
authors: Translational Cancer Research Unit, Laboratory of Pathology, Antwerp University, Antwerp, Belgium; Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium. Electronic address: luc.dirix@gza.be.
authors: Luc
authors: L
authors: Dirix
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: p.berns@erasmusmc.nl.
authors: Els M J J
authors: EM
authors: Berns
authors: Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: m.p.h.m.jansen@erasmusmc.nl.
authors: Maurice P H M
authors: MP
authors: Jansen
mesh_terms: D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058534:Class I Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005838:Genotype; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D009154:Mutation / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D059467:Transcriptome / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C015246:LRG1 protein, human; D035683:MicroRNAs; D012333:RNA, Messenger; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human
keywords: Breast cancer; First line aromatase inhibitors therapy; LRG1; PIK3CA mutations